Lyell Immunopharma (LYEL) Return on Sales (2020 - 2026)
Lyell Immunopharma (LYEL) reported Return on Sales of 516.08% for Q1 2026, down 33196.0% on a YoY basis from N/an in Q1 2025, and down 114.0% sequentially from 241.16% in Q4 2025.
Lyell Immunopharma (LYEL) Return on Sales (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Return on Sales data on file, last reported at 516.08% in Q1 2026.
- For the quarter ending Q1 2026, Return on Sales fell 33196.0% year-over-year to 516.08%; the trailing twelve-month figure through Mar 2026 stood at 150.18% (down 497.0% YoY), and the FY2025 full-year result was 79.6%, up 3808.0% from the prior year.
- Return on Sales retreated to 516.08% in Q1 2026, from 241.16% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.04% in Q2 2022 to a low of 627.93% in Q3 2022.
- A 5-year average of 175.97% and a median of 99.6% in 2024 frame the typical range for Return on Sales.
- Across the five-year window, Return on Sales sank 62771 bps in 2022 and soared 59991 bps in 2023, its largest moves.
- Tracing LYEL's Return on Sales over 5 years: stood at 0.04% in 2022, then tumbled by 593121 bps to 236.03% in 2023, then sank by 116 bps to 510.05% in 2024, then surged by 53 bps to 241.16% in 2025, then plunged by 114 bps to 516.08% in 2026.
- Business Quant data shows LYEL's Return on Sales at 516.08% in Q1 2026, 241.16% in Q4 2025, and 68.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 0.00% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -516.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -516.08% |
| Dec 31, 2025 | -241.16% |
| Sep 30, 2025 | -68.11% |
| Jun 30, 2025 | -144.33% |
| Mar 31, 2025 | -184.12% |
| Dec 31, 2024 | -510.05% |
| Sep 30, 2024 | -36.59% |
| Jun 30, 2024 | -99.60% |
| Mar 31, 2024 | -249.70% |
| Dec 31, 2023 | -236.03% |
| Sep 30, 2023 | -28.02% |
| Jun 30, 2023 | -33.63% |
| Mar 31, 2023 | -12.82% |
| Dec 31, 2022 | -0.04% |
| Sep 30, 2022 | -627.93% |
| Jun 30, 2022 | -0.04% |
| Mar 31, 2022 | -3.17% |
| Dec 31, 2021 | -0.62% |
| Sep 30, 2021 | -0.22% |
| Jun 30, 2021 | -0.66% |